Shanghai Hengrui Pharmaceutical Co., Ltd.
3 clinical trials · 3 recruiting · INDUSTRY
Trials by Shanghai Hengrui Pharmaceutical Co., Ltd.
RECRUITINGPhase 1 / Phase 2NCT05410730
A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
The study is to evaluate the safety and tolerability of SHR-1501 alone or in combination with BCG or SHR-1316 in the patients with NMIBC, and to determine the RP2D of SHR-1501 in...
Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.Enrolling: 1501 location
High-risk NMIBC
RECRUITINGPhase 1NCT06108492
A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk...
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-2005 for Intravesical perfusion in...
Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.Enrolling: 1701 location
Intermediate and High-risk Non-muscle Invasive Bladder Cancer
RECRUITINGPhase 1 / Phase 2NCT06474468
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal...
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic...
Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.Enrolling: 1481 location
Advanced or Metastatic Esophageal Cancer